A novel murine system for validating the specific targeting of peptides to light chain associated (AL) amyloid

Light-chain amyloidosis (AL) is the most common form of systemic amyloid disease. In the US, there are an estimated 4000 new cases each year. Although novel immunotherapies are in clinical trials [...